|1.||Jones, Ronald N: 3 articles (05/2012 - 02/2002)|
|2.||Prince, W T: 2 articles (01/2015 - 05/2013)|
|3.||Ivezic-Schoenfeld, Z: 2 articles (01/2015 - 05/2013)|
|4.||Paukner, Susanne: 2 articles (05/2012 - 03/2012)|
|5.||Ivezic-Schoenfeld, Zrinka: 2 articles (05/2012 - 03/2012)|
|6.||Biedenbach, Douglas J: 2 articles (05/2012 - 03/2012)|
|7.||Sader, Helio S: 2 articles (05/2012 - 03/2012)|
|8.||Keam, Susan J: 2 articles (01/2008 - 01/2008)|
|9.||Yang, Lily P H: 2 articles (01/2008 - 01/2008)|
|10.||Schwarz, Stefan: 1 article (06/2015)|
05/01/2013 - "This study investigated the potential of the novel systemic pleuromutilin antibiotic BC-3781 to treat patients with an acute bacterial skin and skin structure infection (ABSSSI) caused by a Gram-positive pathogen. "
05/01/2013 - "Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections."
05/01/2012 - "BC-3781 is an investigational semi-synthetic pleuromutilin antibiotic, which recently finished a clinical Phase 2 trial in acute bacterial skin and skin structure infections. "
03/01/2012 - "Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections."
01/01/2015 - "BC-3781, a pleuromutilin antimicrobial agent, is being developed for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia. "
01/01/2015 - "Sequence types and pleuromutilin susceptibility of Brachyspira hyodysenteriae isolates from Italian pigs with swine dysentery: 2003-2012."
04/01/2004 - "Between 1997 and 2001, the MIC50 and MIC90 of tiamulin increased from 0.062 and 0.25 microg ml, respectively, to 1.0 and 4.0 microg ml. Valnemulin MIC50 and MIC90 were < or = 0.031 microg ml in 1997 and by 2001 were respectively, 2.0 and 8.0 microg ml. The increase in MICs of tiamulin and valnemulin demonstrated in this study reflect the intensity of pleuromutilin use in the treatment of swine dysentery in the Czech Republic."
01/01/2013 - "Polyclonal and monoclonal antibodies against valnemulin, a new semi-synthetic antibiotic derivative of pleuromutilin administered to treat swine dysentery and pneumonia, were generated. "
04/01/2013 - "Retapamulin is a newer topical agent of pleuromutilin class approved by the Food and Drug Administration for treatment of impetigo in children and has been recently made available in the Indian market. "
10/01/2010 - "In 2007, retapamulin was the first agent for human use approved in the pleuromutilin class of antibacterials in the United States (U.S.), and is the first topical antibacterial indicated to treat impetigo in over 20 years. "
04/01/2009 - "Retapamulin is a new topical pleuromutilin antibiotic for the treatment of skin and skin-structure infections, including impetigo. "
08/01/2014 - "Retapamulin, a topical pleuromutilin that selectively inhibits bacterial protein synthesis, is approved for treatment of impetigo and secondarily infected traumatic lesions in adults and in children older than 9 months of age. "
|6.||Anti-Bacterial Agents (Antibiotics)